AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01275664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Transdermal Patch
Description: Apply one patch to upper arm
Study NCT01275664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Ancillary studies
Study NCT01275664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01826760 — intervention group
Intervention type: OTHER
Intervention: Using training and testing groups to construct ANN based on laboratory tests
Study NCT05137613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One visit root canal retreatment
Description: The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
Study NCT02942082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACP oral care gel
Description: a desensitizing agent will be applied on tooth before and/or after bleaching
Study NCT02942082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glycrin
Description: glycrin will be applied on tooth surface before and/or after bleaching
Study NCT03487939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Study NCT03759704 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized 13CPyruvate
Description: Bolus injection of study drug during MRSI.
Study NCT02182713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulfate/Ipratropium bromide
Description: Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
Study NCT02182713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol sulfate/Ipratropium bromide
Description: Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
Study NCT02182713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol 100 mcg per puff
Study NCT05137613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two visit root canal retreatment
Description: The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
Study NCT02182713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol 100 mcg per puff
Study NCT02840149 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-DOTATATE PET/CT
Description: 68Ga-DOTATATE PET/CT scan
Study NCT03402581 — intervention group
Intervention type: DEVICE
Intervention: c-mac laryngoscope
Description: type of laryngoscopes
Study NCT02567032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
Study NCT02567032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study NCT03722628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MMP1 genotypes polymorphism
Description: Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
Study NCT01675115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNG-1
Description: BNG-1 3 grams TID for 4 weeks
Study NCT01675115 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg QD for 4 weeks
Study NCT00860431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: 6g/day (3 times a day)
Study NCT03977298 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
Study NCT03977298 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
Study NCT02188407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: MAC 3-5 V% during surgery
Study NCT02188407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol group (P group)- The group anaesthesied with propofol
Study NCT04803162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution manometry
Description: The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
Study NCT04803162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum biomarkers
Description: The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
Study NCT04803162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastrointestinal Quality of Life index
Description: The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
Study NCT04803162 — intervention group
Intervention type: DRUG
Intervention: Omeprazole 20 MG Oral Tablet
Description: The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
Study NCT02992964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
Study NCT01878864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge
Study NCT01878864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-adrenalin injection
Study NCT01174849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
Study NCT01174849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium.
Study NCT01174849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBO
Description: COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
Study NCT03354338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
Study NCT03354338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
Study NCT03271125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
Study NCT03271125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance
Description: Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
Study NCT03820063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC-Pz
Description: * Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles.
Study NCT01798628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
Study NCT03977298 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CTG
Description: CTG will be positioned in the buccal aspect of the peri-implant tissue
Study NCT04189757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04356027 — intervention group
Intervention type: PROCEDURE
Intervention: ICA (Invasive Coronary Angiography)
Description: Patients will undergo a Pre-PCI Angiography
Study NCT04356027 — intervention group
Intervention type: PROCEDURE
Intervention: OCT
Description: OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
Study NCT04356027 — intervention group
Intervention type: PROCEDURE
Intervention: FFR
Description: FFR will be measured
Study NCT01798628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
Study NCT01798628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Study NCT04356027 — intervention group
Intervention type: OTHER
Intervention: VFR Analysis
Description: VFR will be calculated offline using the OCT pullback images
Study NCT01393951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous and intramuscular
Study NCT02500342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and \<4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study NCT02500342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study NCT00443287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ataciguat (HMR1766)
Description: oral administration
Study NCT02665780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal debridement
Description: teeth cleaning
Study NCT02665780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetylpyridium chloride
Description: mouthrinse
Study NCT00443287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT00443287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: oral administration
Study NCT01524705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Glargine-injectable, variable, once daily (QD), 6 months
Study NCT01524705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Glargine-injectable, variable, once daily (QD), 6 months
Study NCT01524705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin-oral, up to 1000mg, twice daily (BID), 6 months
Study NCT01524705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin-oral, up to 1000mg, twice daily (BID), 6 months
Study NCT01524705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial insulin
Description: Aspart or glulisine or lispro
Study NCT01524705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Injectable, 5mcg, twice daily (BID), 6 months
Study NCT01758471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: glipizide 5mg per pill 5mg tid p.o. for 3 month
Study NCT04511208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Vest
Description: Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
Study NCT01225263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo pills, taken twice daily for 6 months
Study NCT04511208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without cooling vest
Description: Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
Study NCT01706679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle (PBS)
Study NCT03807440 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT03807440 — intervention group
Intervention type: DRUG
Intervention: Sodium Glucose Transporter 2 inhibitor
Description: Sodium Glucose Transporter 2 inhibitor
Study NCT03807440 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl-peptidase 4 inhibitor
Description: Dipeptidyl-peptidase 4 inhibitor
Study NCT03807440 — intervention group
Intervention type: DRUG
Intervention: Glucagon-like peptide 1 agonist
Description: Glucagon-like peptide 1 agonist
Study NCT03575351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT03575351 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: JCAR017
Study NCT01170741 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Tailored Cue Cards
Description: The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
Study NCT03412058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed prior to anti-PD1/PD-L1 treatment initiation
Study NCT01758471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
Study NCT03412058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
Study NCT03412058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: To be performed at disease progression if medically feasible
Study NCT00209690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00209690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02690467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insupen G34x3,5mm
Study NCT02690467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insupen G32x4mm
Study NCT00677963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sulphur hexafluoride, gadopentate dimeglumine
Description: CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
Study NCT03435029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Program (REHACOP)
Description: The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
Study NCT03435029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
Study NCT04576351 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
Study NCT03847337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Screening Tool for Autism in Toddlers (STAT)
Description: Structured autism screening tool
Study NCT03847337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)
Description: Semi-structured autism screening tool
Study NCT00569920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
Study NCT00569920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: natriumchloride 0,9%
Description: iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
Study NCT00569920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
Study NCT04797975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KDS-1000
Description: Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose
Study NCT04797975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline